|Bid||0.0100 x 800|
|Ask||3.0600 x 900|
|Day's Range||2.7000 - 2.9000|
|52 Week Range||1.3500 - 13.0000|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The acquisition is expected to be completed by mid 2019. Once the acquisition is complete the company will continue to operate as ESSA Pharma, and trade on the Nasdaq and TSX-V Market and operating in the United States as ESSA Pharmaceuticals Corp. The terms of the acquisition value Realm's issued and outstanding shares at approximately $21.5 million, which represents a 5 percent premium over Realm's estimated net cash amount of $20.5 million at the closing of the acquisition.
The company began exploring 'strategic options' after a key product failed in midstage clinical testing in September.
Alex Martin became the CEO of Realm Therapeutics Plc (LON:RLM) in 2015. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, Read More...